Dartmouth Hitchcock Medical Center, which is part of the Dartmouth Health system, is the U.S. state of New Hampshire's only academic medical center. DHMC is a 396-inpatient bed hospital and serves as a major tertiary-care referral site for patients throughout northern New England.

There are 396 beds in Dartmouth Hitchcock Medical Center.

During the past decade, Dartmouth Hitchcock Medical Center conducted 655 clinical trials. In the 10-year time frame, 655 clinical trials started and 426 clinical trials were completed, i.e. on average, 65% percent of trials that started reached the finish line to date. In the past 5 years, 270 clinical trials started and 247 clinical trials were completed. i.e. 91.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Dartmouth Hitchcock Medical Center" #1 sponsor was "Dartmouth-Hitchcock Medical Center" with 249 trials, followed by "National Cancer Institute (NCI)" with 166 trials sponsored, "Children's Oncology Group" with 59 trials sponsored, "Alliance for Clinical Trials in Oncology" with 28 trials sponsored and "SWOG Cancer Research Network" with 28 trials sponsored. Other sponsors include 654 different institutions and companies that sponsored additional 350 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dartmouth Hitchcock Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 190 trials as a collaborator, "NRG Oncology" with 38 trials as a collaborator, "Dartmouth-Hitchcock Medical Center" with 33 trials as a collaborator, "Dartmouth College" with 20 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 15 trials as a collaborator. Other collaborators include 690 different institutions and companies that were collaborators in the rest 409 trials.

According to Clinical.Site data, the most researched conditions in "Dartmouth Hitchcock Medical Center" are "Breast Cancer" (29 trials), "Cystic Fibrosis" (19 trials), "Acute Myeloid Leukemia" (17 trials), "Coronary Artery Disease" (16 trials) and "Epilepsy" (16 trials). Many other conditions were trialed in "Dartmouth Hitchcock Medical Center" in a lesser frequency.

Most popular intervention types in "Dartmouth Hitchcock Medical Center" are "Drug" (687 trials), "Other" (314 trials), "Biological" (190 trials), "Device" (166 trials) and "Procedure" (158 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (128 trials), "Placebo" (120 trials), "Quality-of-Life Assessment" (74 trials), "Cyclophosphamide" (50 trials) and "Carboplatin" (48 trials). Other intervention names were less common.

The vast majority of trials in "Dartmouth Hitchcock Medical Center" are 1062 trials for "All" genders, 100 trials for "Female" genders and 20 trials for "Male" genders.

Currently, there are 440 active trials in "Dartmouth Hitchcock Medical Center". 5 are not yet recruiting, 205 are recruiting, 219 are Active, not recruiting, and 11 are Enrolling by invitation. In total, there were 576 completed trials in Dartmouth Hitchcock Medical Center, 13 suspended trials, and 114 terminated clinical trials to date.

Out of the total trials that were conducted in Dartmouth Hitchcock Medical Center, 80 "Phase 1" clinical trials were conducted, 350 "Phase 2" clinical trials and 355 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 42 trials, and there were also 259 trials that are defined as “Not Applicable".

Dartmouth Hitchcock Medical Center has several departments that took part in Clinical trials: "Dartmouth Hitchcock Medical Center Dept of Neurology" - 5 trials, "Dartmouth-Hitchcock Medical Center - Section of Dermatology" - 4 trials, "Dartmouth-Hitchcock Medical Center - Spine Center" - 3 trials, "Dartmouth-Hitchcock Medical Center, Rheumatology 5C" - 3 trials, "Dartmouth Medical School Neuroscience Center" - 2 trials, "Rheumatology Research Group" - 2 trials